^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells

    i
    Other names: CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
    Associations

    News

    Trials
    Company:
    SZGIMI
    Drug class:
    CD123-targeted CAR-T immunotherapy, CD33-targeted CAR-T immunotherapy, CLL-1-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    23d
    Multiple CAR-T Cell Therapy Targeting AML (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2029 | Trial primary completion date: Jul 2021 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD33 (CD33 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells